Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Isis Pharmaceuticals (NASDAQ:ISIS) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Isis' business and see what CAPS investors are saying about the stock right now.

Isis facts

Headquarters (Founded)

Carlsbad, Calif. (1989)

Market Cap

$999 million



Trailing-12-Month Revenue

$119 million


Founder/CEO Dr. Stanley Crooke
COO/CFO Lynne Parshall

Trailing-12-Month Return on Equity


Compound Annual Revenue Growth (Over Past 5 Years)



$612 million / $140 million

Other Highly Rated Biotech Stocks

Gilead Sciences (NASDAQ:GILD)

CAPS Members Bullish on ISIS Also Bullish on

Johnson & Johnson (NYSE:JNJ)

CAPS Members Bearish on ISIS Also Bearish on

Citigroup (NYSE:C)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95% of the 539 members who have rated Isis believe the stock will outperform the S&P 500 going forward. These bulls include tenmiles, the sixth ranked investor in all of CAPS, and PaladinRider.

Only two days ago, tenmiles highlighted the stock's recent weakness as a great chance to pounce: "Shorts have had some recent fun with this one, but will likely find some technical support around $10 after its spanking. Would seem to represent a fairly cheap 'call option' on a good molecule in the 2010-11 timeframe."

In an earlier pitch, PaladinRider helped Fools make some sense of Isis' antisense technology:

Antisense play that will either be a huge winner or a dismal failure. Been following this company for many years through trials that have fizzled out. However, the current pipeline looks promising and it is one resilient company that takes a licking and keeps on ticking. Highly speculative but could produce a major breakthrough in the treatment of cancer, Type 2 diabetes, multiple sclerosis, etc. Great alliances with Big Pharma also give one hope. Isis is not for the faint of heart -- it's almost a cult classic!

What do you think about Isis, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. The CAPS community is waiting to hear your opinions. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, and Apple is a selection of Stock Advisor. The Fool's disclosure policy always gets a perfect score.